Evidence map›Paper›PMID 35001352›Full record

ArticleImmunologic research2022

B cell repertoire in patients with a novel BTK mutation: expanding the spectrum of atypical X-linked agammaglobulinemia.

Ori Toker, Arnon Broides, Atar Lev, Amos J Simon, Orli Megged, Oded Shamriz, Yuval Tal, Raz Somech, Yu Nee Lee, Amit Nahum

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Ori TokerFaculty of Medicine, The Allergy and Immunology Unit, Hebrew University of Jerusalem, Shaare Zedek Medical Center, 12 Bayit Street, 91031, Jerusalem, Israel. oritoker@gmail.com.ORCID 0000-0002-5248-3193
Arnon BroidesImmunology Clinic, Soroka University Medical Center, Beer-Sheva, Israel.
Atar LevPediatric Department A and the Immunology Service, Sackler" Faculty of Medicine, Jeffrey Modell Foundation Center; "Edmond and Lily Safra" Children's Hospital, Sheba Medical Center, Tel Aviv University, Tel-Aviv, Israel.
Amos J SimonPediatric Department A and the Immunology Service, Sackler" Faculty of Medicine, Jeffrey Modell Foundation Center; "Edmond and Lily Safra" Children's Hospital, Sheba Medical Center, Tel Aviv University, Tel-Aviv, Israel.
Orli MeggedFaculty of Medicine, The Pediatric Infectious Diseases Unit, Hebrew University of Jerusalem, Shaare Zedek Medical Center, Jerusalem, Israel.
Oded ShamrizThe Lautenberg Center for Immunology and Cancer Research, Faculty of Medicine, Institute of Medical Research Israel-Canada, Hebrew University of Jerusalem, Jerusalem, Israel.
Yuval TalAllergy and Clinical Immunology Unit, Department of Medicine, Faculty of Medicine, Hadassah Medical Organization, Hebrew University of Jerusalem, Jerusalem, Israel.
Raz SomechPediatric Department A and the Immunology Service, Sackler" Faculty of Medicine, Jeffrey Modell Foundation Center; "Edmond and Lily Safra" Children's Hospital, Sheba Medical Center, Tel Aviv University, Tel-Aviv, Israel.
Yu Nee Lee *Pediatric Department A and the Immunology Service, Sackler" Faculty of Medicine, Jeffrey Modell Foundation Center; "Edmond and Lily Safra" Children's Hospital, Sheba Medical Center, Tel Aviv University, Tel-Aviv, Israel.
Amit Nahum *Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Hebrew University of Jerusalem · ILTel Aviv University · ILBen-Gurion University of the Negev · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

X-linked agammaglobulinemia (XLA) is caused by mutations in the Bruton tyrosine kinase) BTK) gene. Affected patients have severely reduced amounts of circulating B cells. Patients with atypical XLA may have residual circulating B cells, and there are few studies exploring these cells' repertoire. We aimed to study the B cell repertoire of a novel hypomorphic mutation in the BTK gene, using the next generation sequencing (NGS) technology. Clinical data was collected from our clinical records. Real-time PCR was used to determine KREC copies, and NGS was used to determine the immunoglobulin (Ig) heavy chain (IgH) repertoire diversity. Both patients had a relatively mild clinical and laboratory phenotype, residual BTK protein expression, and the same novel mutation in the BTK gene, c.1841 T > C, p. L614P. Signal-joint kappa-deleting recombination excision circles (sj-KREC) for both patients were completely absent reflecting lack of naïve B cells. The intron RSS-Kde coding joints (cj) were significantly reduced, reflecting residual replicating B cells. NGS displayed restricted IgH repertoire with highly uneven distribution of clones, especially for Pt2. We report a novel BTK mutation, c.1841 T > C (p. L614P) that is associated with a relatively mild phenotype. We conclude that the IgH repertoire in atypical XLA is restricted with highly uneven distribution of clones. This phenomenon may be explained by extremely reduced to non-existent levels of BTK in B cells. This report sheds further light on atypical cases of XLA.

Indexed as

AgammaglobulinemiaGenetic Diseases, X-LinkedAgammaglobulinaemia Tyrosine KinaseHumansMutationAgammaglobulinaemia Tyrosine KinaseAgammaglobulinemiaBTKIgH repertoire diversityKRECXLA

Identifiers

PMID35001352
OpenAlexW4206594730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.